

1 **Original Research Article**

2

3 **Association between antihypertensive combinations and postoperative mortality**  
4 **and functional decline: a nationwide survey of Japanese adults undergoing major**  
5 **surgeries**

6

7 Rena Suzukawa<sup>1</sup>, Shintaro Mandai<sup>1\*</sup>, M.D., Ph.D., Yuta Nakano<sup>1</sup>, M.D., Shunsuke  
8 Inaba<sup>1</sup>, M.D., Hisazumi Matsuki<sup>1</sup>, M.D., Yutaro Mori<sup>1</sup>, M.D., Ph.D., Fumiaki Ando<sup>1</sup>,  
9 M.D., Ph.D., Takayasu Mori<sup>1</sup>, M.D., Ph.D., Koichiro Susa<sup>1</sup>, M.D., Ph.D., Soichiro  
10 Iimori<sup>1</sup>, M.D., Ph.D., Shotaro Naito<sup>1</sup>, M.D., Ph.D., Eisei Sohara<sup>1</sup>, M.D., Ph. D.,  
11 Tatemitsu Rai<sup>2</sup>, M.D., Ph. D., Kiyohide Fushimi<sup>3</sup>, M.D., Ph.D., Shinichi Uchida<sup>1</sup>, M.D.,  
12 Ph.D.

13

14 <sup>1</sup>Department of Nephrology, Graduate School of Medical and Dental Sciences, Tokyo  
15 Medical and Dental University, 1-5-45 Yushima, Bunkyo, Tokyo 113-8519, Japan

16 <sup>2</sup>Department of Nephrology and Hypertension, Dokkyo Medical University, 880  
17 Kitakobayashi, Mibu, Shimotsuga, Tochigi, 321-0293, Japan

18 <sup>3</sup>Department of Health Policy and Informatics, Graduate School of Medical and Dental  
19 Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo, Tokyo  
20 113-8519, Japan

21

22   Suzukawa R and Mandai S contributed equally.

23

24   Short title: Antihypertensive class and postoperative outcomes

25

26   \*Corresponding Author: Shintaro Mandai (ORCID iD: 0000-0001-6709-306X)

27   Department of Nephrology, Graduate School of Medical and Dental Sciences, Tokyo

28   Medical and Dental University, 1-5-45 Yushima, Bunkyo, Tokyo 113-8519, Japan

29   Tel: +81-3-5803-5214; Fax: +81-3-5803-5215; E-mail: [smandai.kid@tmd.ac.jp](mailto:smandai.kid@tmd.ac.jp)

30

31   Total word count: 3,543

32 **Abstract**

33 **Background:** Considering the limited information available regarding the impact of  
34 antihypertensive classes on mortality and physical function during hospitalization, we  
35 aimed to clarify the impact of six antihypertensive classes, namely thiazide/thiazide-like  
36 diuretics (TH), calcium receptor blockers (CCBs), renin–angiotensin–aldosterone  
37 system inhibitors (RASIs), mineral corticoid receptor antagonists,  $\alpha$ -blockers, and  
38  $\beta$ -blockers, on outcomes in adult patients undergoing major surgeries.

39 **Methods:** This study was a subanalysis of a nationwide observational cohort study  
40 involving Japanese adults undergoing major surgeries from 2018 to 2019 using an  
41 administrative claims database. We recruited 473,327 antihypertensive medication users  
42 and 376,583 nonusers aged  $\geq 50$  years who underwent six different types of surgeries,  
43 including coronary artery bypass grafting (CABG), thoracic lobectomy, orthopedic  
44 surgery, hepatopancreatobiliary surgery, gastrointestinal resection, and urological  
45 surgery. The risk for overall death or functional decline, defined as a  $\geq 5$ -point decrease  
46 in the Barthel Index score during hospitalization, was determined using multivariable  
47 logistic regression models.

48 **Results:** All-cause in-hospital deaths occurred in 5,777 (1.2%) users and 2,657 (0.7%)  
49 nonusers. Functional decline was observed in 42,930 (9.2%) users and 22,550 (6.0%)

50 nonusers. Among single class users, RASi use had a multivariable odds ratio (OR) of  
51 0.77 (95% confidence interval (CI) 0.63–0.93 vs. TH) for the composite of mortality  
52 and functional decline.  $\beta$ -Blocker use was associated with an increased risk for  
53 functional decline (OR 1.27, 95% CI 1.01–1.60 vs. TH). Among the recipients of the  
54 two medication classes, TH/RASi usage was associated with the lowest risk for  
55 composite outcome (OR 0.68, 95% CI 0.60–0.77 vs. TH/CCB). Among the recipients of  
56 the three or more medication classes, TH/CCB/RASi or TH/CCB/RASi/other displayed  
57 the lowest odds for composite outcome (OR 0.72, 95% CI 0.49–0.82 vs. TH/CCB/other;  
58 OR 0.63, 95% CI 0.49–0.82 vs. TH/CCB/others). A stratified analysis revealed that  
59 RASi users had a lower OR for the composite outcome after major surgery categories  
60 except CABG than non-RASi users.

61 **Conclusions:** RASis were associated with decreased risk of postoperative mortality and  
62 functional decline regardless of the number of antihypertensive classes or surgery type.  
63 Managing hypertension through multidrug combinations, including RASis, may  
64 mitigate mortality and loss of physical function during the perioperative period.

65

## 66 **Clinical Perspective**

67 What is new?

68 ● This nationwide observational cohort study of Japanese adults undergoing major  
69 surgeries from 2018 to 2019 using an administrative claims database showed  
70 that all-cause inhospital deaths occurred in 5,777 (1.2%) antihypertensive users  
71 and 2,657 (0.7%) nonusers, whereas functional decline was observed in 42,930  
72 (9.2%) antihypertensive users and 22,550 (6.0%) nonusers.

73 ● We found that an increase in the number of antihypertensive classes used,  
74 indicative of patients with treatment-resistant hypertension, was associated with  
75 a higher risk of mortality and loss of physical function, partly attributed to loop  
76 diuretic use for congestion.

77 What are the clinical implications?

78 ● This study determined combinations of antihypertensive drugs that potentially  
79 improve the outcomes of antihypertensive users undergoing major surgeries,  
80 with the favorable regimens including RASis independent of the number of  
81 antihypertensive classes used.

82 ● After undergoing all major surgery categories except CABG, patients on RASis  
83 were at a lower risk of death and functional decline than those who were treated  
84 with other antihypertensive classes.

85

86 **Keywords:** hypertension, antihypertensive class, surgery, physical function,

87 renin–angiotensin–aldosterone system inhibitor

88

89 **Nonstandard Abbreviations and Acronyms**

90 ACEi        angiotensin-converting enzyme inhibitor

91 AKI         acute kidney injury

92 ADL         activities of daily living

93 AHT         acute hypertension

94 ARB         angiotensin II receptor blocker

95 BMI         body mass index

96 CABG        coronary artery bypass grafting

97 CCB         calcium channel blocker

98 CI           confidence intervals

99 CKD         chronic kidney disease

100 CVD         cardiovascular disease

101 DM          diabetes mellitus

102 DPC         diagnosis procedure combination

103 ESKD        end-stage kidney disease

104 ICD-10      International Classification of Disease and Related Health Problems,

105 10th Revision

106 IQR         interquartile range

107 MRA         mineral corticoid receptor antagonist

108 OR          odds ratio

109 RAS renin–angiotensin system  
110 RASi renin–angiotensin–aldosterone system inhibitor  
111 ROS reactive oxygen species  
112 TH thiazide/thiazide-like diuretics

113

## 114 **Introduction**

115 The proportion of patients with hypertension continues to increase globally. The  
116 number of adult patients with hypertension doubled from 1990 to 2019, affecting nearly  
117 1,300 million people worldwide [1]. Although recent advances in antihypertensive  
118 medications and their widespread availability have improved hypertension control in  
119 this population, the prevalence of treatment-resistant hypertension requiring a  
120 combination of multiple antihypertensive classes has continued to increase [2-5]. When  
121 caring for patients with hypertension, the prevention of chronic systemic organ  
122 dysfunction, hospitalization, acute kidney injuries (AKI), and death caused by acute  
123 hypertension (AHT) is of considerable importance [6]. We previously reported an  
124 increase in absolute death and urgent dialysis due to AHT from 2010 to 2019 among  
125 hospitalized Japanese patients [6]. Given the lack of comprehensive investigations on  
126 the effective combination of antihypertensive classes and the mostly empiric evidence  
127 available [4], understanding the effects of various antihypertensive medications and

128 their management approaches for both in- and outpatients has been of notable interest  
129 among physicians.

130 The decline in activities of daily living (ADLs) and frailty related to  
131 hospitalization have also been an enormous health concern for inpatients, given the  
132 exponential increase in the aging population globally. Previous studies have established  
133 that the use of angiotensin-converting enzyme inhibitors (ACEis) has long-term effects  
134 on muscle strength [7,8]. The use of angiotensin II receptor blockers (ARBs) promotes  
135 enhanced exercise capacity among patients with heart failure [9]. In contrast, our studies  
136 showed that patients taking loop diuretics were at an increased risk of developing  
137 sarcopenia [10,11], with subsequent studies reporting the same correlation among  
138 patients with heart failure and hepatopathy [12-14]. However, no study has focused on  
139 the effects of antihypertensive class or loop diuretics during hospitalization under acute  
140 care settings, i.e., in patients with severe diseases (e.g., cardiovascular diseases [CVDs],  
141 infectious diseases, or major surgeries). We evaluated the impact of continued empirical  
142 antihypertensive drug administration during hospitalization on postoperative outcomes,  
143 including mortality and physical function, after major surgeries.

144 The current study aimed to determine the most effective monotherapy or  
145 combination therapy among six antihypertensive classes (i.e., thiazide/thiazide-like



146 diuretics [TH], calcium receptor blockers [CCBs], renin–angiotensin–aldosterone  
147 system inhibitors [RASIs], mineral corticoid receptor antagonists [MRAs],  $\alpha$ -blockers,  
148 and  $\beta$ -blockers) and loop diuretics, which helps lower the risk for postoperative  
149 mortality and functional decline among patients aged 50 and older who underwent  
150 major surgeries during hospitalization. We also aimed to investigate whether the type of  
151 major surgery (i.e., coronary artery bypass grafting [CABG], thoracic lobectomy,  
152 orthopedic surgery, hepatopancreatobiliary surgery, gastrointestinal resection, and  
153 urological surgery) altered the association between antihypertensive class and  
154 postoperative outcomes.

155

## 156 **Methods**

### 157 *Study design and participants*

158 This study was a *posthoc* subanalysis of a national survey on postoperative  
159 outcomes among Japanese adults undergoing major surgeries [15]. We used an  
160 administrative claims database, the Diagnosis Procedure Combination (DPC) inpatient  
161 database, to obtain data from 2018 to 2019 [6,15,16]. This dataset comprises  
162 information obtained from over 1000 hospitals, including all 82 teaching hospitals, and  
163 covers half or more of inpatient cases throughout Japan. The available information

164 included diagnosis and comorbidities upon hospital admission coded according to the  
165 International Classification of Disease and Related Health Problems, 10th Revision [14].  
166 The datasets also included information on patients' age, sex, body mass index (BMI),  
167 the Charlson comorbidity index [17], which was updated for risk adjustment [18],  
168 ADLs upon admission and discharge, and discharge status.

169 A total of 15,422,773 eligible cases were identified. The criteria for study  
170 inclusion included age  $\geq 50$  years, hospitalization  $\geq 24$  h, and patients undergoing any of  
171 the defined major surgeries. Major surgeries were previously defined as invasive  
172 operative procedures, including CABG, thoracic lobectomy, orthopedic surgery (hip or  
173 knee arthroplasty, laminectomy or spinal fusion, and surgery for hip fracture or  
174 dislocation), hepatopancreatobiliary surgery (hepatic lobectomy, cholecystectomy, and  
175 pancreatectomy), gastrointestinal resection (esophagectomy, gastrectomy, and  
176 colectomy), and urological surgery (cystectomy and nephrectomy) [15,19]. The  
177 exclusion criteria were as follows: second or later admissions; patients with incomplete  
178 information on BMI, the Barthel Index, and admission type (emergency admission or  
179 not); those who underwent multiple surgery types; and dependence on maintenance  
180 dialysis therapy. Dependence on hemodialysis or peritoneal dialysis was determined  
181 from the coding of patient care procedures (chronic maintenance hemodialysis with  $<4$

182 h per session,  $\geq 4$  h but  $< 5$  h per session,  $\geq 5$  h per session or chronic maintenance

183 hemodiafiltration or continuous peritoneal dialysis) [17].

184 Our study protocol was approved by the ethics committee of Tokyo Medical and

185 Dental University. The need for informed consent was waived because the data were

186 anonymized. The study was conducted in accordance with the ethical principles of the

187 Declaration of Helsinki. The data used for the study analyses are available from the

188 corresponding author S.M. upon reasonable request.

189

#### 190 *Patient characteristics*

191 We calculated the Barthel Index scores upon admission and discharge based on

192 10 functional abilities, including feeding, bathing, grooming, dressing, bowel control,

193 bladder control, toileting, chair transfer, ambulation, and climbing stairs [20]. Barthel

194 Index scores ranged from 0 to 100 at 5-point increments, with 0 indicating complete

195 bed-ridden status and 100 indicating full independence of physical functions. Other

196 patient information on admission included age, sex, BMI, dependence on urgent or

197 maintenance kidney replacement therapy, updated Charlson comorbidity index,

198 excluding renal disease [17,18], comorbidity, surgery type, admission type (emergency

199 or elective admission), and fiscal year. We used the following age strata for the

200 analyses: 50–59, 60–69, 70–79, and  $\geq 80$  years [21]. On the basis of previous studies,

201 antihypertensive medications were classified into six groups, including TH, CCBs,

202 RASIs, MRAs,  $\alpha$ -blockers, and  $\beta$ -blockers [22, 23]. Thiazide-like diuretics without a

203 benzothiadiazide structure, such as indapamide and metolazone, were also categorized  
204 under TH. Only dihydropyridines were included as CCBs in this study. RASis included  
205 ACEis and ARBs. Notably,  $\alpha/\beta$ -blockers were included under  $\beta$ -blockers. Loop  
206 diuretics were recognized when used both orally and intravenously.

207

## 208 *Outcomes*

209 The primary outcome was the composite of overall inhospital death and decline  
210 in physical function, which was defined as a 5-point lower Barthel Index score [24] at  
211 discharge than at admission. Patients were followed up until discharge, transfer, or  
212 inhospital death.

213

## 214 *Data analyses*

215 Data were presented as number (percentage) or median (interquartile range  
216 [IQR]). Logistic regression models were used to assess the association between  
217 antihypertensive medication and loop diuretics and the risk for mortality or functional  
218 decline, adjusting for potential confounding measurements, including age, sex, type of  
219 major surgeries, BMI, Barthel Index score upon admission, diabetes mellitus (DM),  
220 CVD, chronic kidney disease (CKD), emergency admission, and year of admission. We  
221 conducted subgroup analyses using logistic regression models to determine the

222 association between antihypertensive class and outcomes according to major surgery  
223 type. All statistical analyses were performed using Stata version 15.0 (Stata Corp.,  
224 College Station, TX, United States), with  $P < 0.05$  indicating statistical significance.

225

## 226 **Results**

### 227 *Patient characteristics*

228 We identified 15,422,773 patients from a Japanese national inpatient database  
229 between 2018 and 2019 (Fig. S1). Subjects aged 50 years and older who underwent  
230 major operations during hospitalization lasting for at least 24 h were included (n =  
231 1,283,540). Subsequently, those on their second or later admissions; those without  
232 complete information on BMI, Barthel Index score, or emergency admission; and those  
233 who underwent multiple surgeries or received maintenance dialysis were excluded. In  
234 total, 849,910 subjects were included in the analysis.

235 Table 1 summarizes the demographics and characteristics of the study cohort.

236 Among the 849,910 patients, 473,327 (56%) were taking at least one class of  
237 antihypertensive medication. Antihypertensive users and nonusers had a median age  
238 (IQR) of 76 (69–82) years and 70 (63–78) years, female percentage of 49% and 50%,  
239 and median BMI of 23.4 (20.9–26.0) kg/m<sup>2</sup> and 22.5 (20.2–24.9) kg/m<sup>2</sup>, respectively. A

240 larger proportion of antihypertensive users than nonusers had a low Barthel Index score.  
241 The prevalence of comorbidities, including CVD, DM, and CKD, was higher among  
242 antihypertensive users than among nonusers. Patients were also stratified according to  
243 the type of major surgery that they underwent during hospitalization. Among the six  
244 types of major surgeries (CABG, thoracic lobectomy, orthopedic surgery,  
245 hepatopancreatobiliary surgery, gastrointestinal resection, and urological surgery),  
246 orthopedic surgery was the most common in both groups (45% and 37%, respectively),  
247 followed by gastrointestinal resection and esophagectomy (20% and 25%, respectively).

248

249 *Effects of the number of antihypertensive classes on postoperative outcomes*

250 After a median follow-up of 17 (IQR, 10–27) days, all-cause in-hospital deaths  
251 were observed in 5,777 patients (1.2%) out of 473,327 antihypertensive users and 2,657  
252 patients (0.7%) out of 376,583 nonusers. Functional decline was observed in 22,550  
253 (6.0%) nonusers and 42,930 (9.2%) users. Figure 1 displays the prevalence of all-cause  
254 in-hospital death and functional decline after survival according to age category. The  
255 proportions of mortality and functional decline were higher among patients on more  
256 antihypertensive classes than among those on no or fewer antihypertensive classes. This

257 indicates a significant association between resistance and antihypertensive treatment

258 and the crude mortality rate and decline in ADLs (Figure 1)

259           Thereafter, multivariable logistic regression models were created to determine

260 the aggregate risk for all-cause in-hospital death and functional decline after survival. In

261 the age- and sex-adjusted model, the odds ratios (ORs) for a composite outcome of

262 mortality and functional decline were 1.20 (95% confidence interval [CI], 1.18–1.23),

263 1.23 (95% CI, 1.20–1.25), 1.42 (95% CI, 1.38–1.47), and 1.57 (95% CI, 1.49–1.65) for

264 users receiving one, two, three, and four or more classes of antihypertensives when

265 compared with nonusers (Table 2). Similarly, in Models 2 and 3, which adjusted for

266 DM, CVD, CKD, emergency admission, and admission year, the use of more

267 antihypertensive classes was associated with a higher risk for the composite outcome.

268 After additionally adjusting for the use of loop diuretics (Model 4), the odds for the

269 composite outcome were comparable between users receiving one, two, three, and four

270 or more classes of antihypertensives. These findings indicate that congestion requiring

271 the use of loop diuretics is a major confounding factor for the association between

272 resistant hypertension and unfavorable postoperative outcomes.

273

274 *Combinations of antihypertensive classes and postoperative outcomes*

275 We then investigated whether differences in postoperative outcomes following  
276 major surgeries were present according to different combinations of antihypertensive  
277 classes among the patients.

278 Among those who used only one of the six antihypertensive classes and loop  
279 diuretics, RASis showed the lowest OR for composite outcome, mortality, and  
280 functional decline (Table 3). With TH as the reference, RASi showed 0.77-, 0.58-, and  
281 0.79-times lower odds for the composite outcome (95% CI, 0.63–0.93;  $P = 0.008$ ),  
282 mortality (95% CI, 0.34–0.99;  $P = 0.045$ ), and functional decline (95% CI, 0.64–0.96;  $P$   
283 = 0.020), respectively, whereas  $\beta$ -blockers showed a 1.27-times higher odds for  
284 functional decline (95% CI, 1.01–1.60;  $P = 0.040$ ; Table 3). Among those who used two  
285 antihypertensive classes, the combination of THs and RASi showed the lowest OR for  
286 each outcome. Compared with TH/CCB, TH and RASi had an OR of 0.68 for the  
287 composite outcome (95% CI, 0.60–0.77;  $P < 0.001$ ; Table 3). Among those who used  
288 three or more classes of antihypertensive, combinations including CCB and RASi  
289 showed the lowest OR for each outcome. In comparison, using the combination of TH,  
290 CCB, and other as the reference, the combination of TH, CCB, and RASi showed odds  
291 of 0.72-, 0.43-, and 0.79-times lower for the composite outcome (95% CI, 0.49–0.82;  $P$   
292 < 0.001), mortality (95% CI, 0.31–0.60;  $P < 0.001$ ), and functional decline (95% CI,



293 0.70–0.89;  $P < 0.001$ ; Table 3), respectively. The use of RASis was significantly  
294 associated with a lower OR for postoperative outcomes regardless of the number of  
295 antihypertensive classes used for treatment. A comparison of those who did and did not  
296 use loop diuretics showed that loop diuretic use consistently resulted in significantly  
297 higher ORs for the composite outcome, mortality, and functional decline regardless of  
298 the number of other antihypertensive medications used (Table S1).

299

300 *Impact of each antihypertensive class on postoperative outcomes according to the type*  
301 *of major surgery*

302 We performed a stratified analysis on the impact of each antihypertensive class  
303 on postoperative outcomes according to six types of major surgeries (CABG, thoracic  
304 lobectomy, orthopedic surgery, hepatopancreatobiliary surgery, gastrointestinal  
305 resection, and urological surgery). Notably, RASis were associated with lower ORs for  
306 the composite outcome of death and functional decline, all-cause in-hospital death, and  
307 survival with functional decline among those who underwent five types of major  
308 surgeries except CABG (Figure 2). Only  $\beta$ -blocker use was associated with better  
309 outcomes among patients who underwent CABG (OR, 0.77; 95% CI, 0.67–0.89).

310

311 **Discussion**

312           The current large-scale epidemiologic cohort study using the Japanese  
313 administrative claims database clarified the effects of antihypertensive drugs on  
314 postoperative mortality and functional decline in patients aged 50 and older. First, we  
315 found that an increase in the number of antihypertensive classes, which indicated  
316 treatment-resistant hypertension, was associated with a higher risk of mortality and loss  
317 of physical function, partly attributed to loop diuretic use needed for congestion. Second,  
318 we determined combinations of antihypertensives that potentially improve the outcomes  
319 of antihypertensive users undergoing major surgeries. The favorable regimens included  
320 RASis independent of the number of antihypertensive classes used. Third, among  
321 patients who underwent any type of major surgery, excluding CABG, those on RASis  
322 were at a lower risk of death and functional decline than those not treated with other  
323 antihypertensive classes.

324           The primary finding of the current study was that patients who received RAS  
325 inhibition had a lower risk for the composite outcome of all-cause in-hospital death and  
326 functional decline after surviving major surgeries than those without RAS inhibition,  
327 independent of the number of antihypertensive classes used. RAS inhibition in patients  
328 treated with ACEi and ARB is known to help decrease skeletal muscle loss [7-9]. A

329 plausible explanation for its underlying pathological mechanism is the suppression of  
330 angiotensin II-induced impairment in protein synthesis, acceleration of protein  
331 breakdown, and loss of appetite. Angiotensin II increases the levels of cytokines and  
332 systemic hormones, including reactive oxygen species, insulin-like growth factor 1,  
333 tumor necrosis factor alpha, interleukin-6, and transforming growth factor beta [7-9,  
334 24-28]. The current study showed that among patients who used a single class of  
335 antihypertensive, those who used RASi had lower odds for the composite outcome of  
336 mortality and functional decline than those who used TH. Among those who received  
337 two classes of antihypertensives, those who received a combination of TH/RASi had an  
338 OR of 0.68 for the composite outcome compared with those on TH/CCB. The favorable  
339 effects of RASis on mortality and functional decline were also observed among those  
340 who used three or more antihypertensive classes. Our data clearly showed that RAS  
341 interfered with functional decline, although pathological analysis at the molecular level  
342 was not conducted.

343         Our findings showed that  $\beta$ -blocker users had a 1.27-fold higher OR for  
344 functional decline than TH users, which is consistent with previous findings on the  
345 association between  $\beta$ -blocker and functional decline in patients with end-stage kidney  
346 disease (ESKD) [29], CVD, and heart failure [30, 31]. In our previous study on a cohort

347 with ESKD,  $\beta$ -blocker users had 2.5-fold higher odds of annual skeletal muscle mass  
348 loss, whereas the use of RASi in combination with other medications minimized the  
349 adverse effects [29]. Notably, only the use of  $\beta$ -blockers was markedly associated with a  
350 lower risk for postoperative composite outcome in patients who underwent CABG.  
351 Therefore, the current study reaffirms the positive effects of RASi on skeletal muscle  
352 mass in acute care settings among patients undergoing major surgeries [29].  
353 Nonetheless, further investigations are needed to uncover the mechanism underlying the  
354 association between RAS inhibition and favorable outcomes after major surgeries,  
355 excluding CABG.

356         Our findings showed that outcomes following major surgeries could be further  
357 improved by combining empirically antihypertensive drugs prescribed. Frailty, often  
358 defined as unintentional weight loss, has been shown to be associated with mortality  
359 among inhospital patients [32], as well as postdischarge patients or outpatients [33-35].  
360 Newly acquired functional decline among older persons owing to hospital admissions is  
361 especially serious given the already high prevalence of frailty among  
362 community-dwelling people in the aging Japanese society [36] and its association with  
363 higher mortality and economic burden. Our findings showed that 9.2% of  
364 antihypertensive drug users and 6.0% of nonusers experienced a decrease in their

365 Barthel Index score during hospitalization, a figure even higher than the 7.4% overall  
366 pooled prevalence of frailty among Japanese community-dwelling people aged 65 and  
367 older reported in a previous review [36]. This suggests that the probability of functional  
368 decline is primarily higher among inpatients and that patients with hypertension are at  
369 substantially higher risk. Thus, combinations of antihypertensive drugs, including  
370 RASis, may improve the clinical outcomes of patients with hypertension by minimizing  
371 functional decline through internal treatment during the acute phase of hospitalization.

372 A substantial proportion of patients worldwide remain resistant to hypertension  
373 treatment and are usually treated with more antihypertensive medication classes.  
374 However, the optimal combinations of antihypertensives are yet to be fully understood.  
375 As expected, our findings showed that the number of antihypertensive classes was  
376 positively correlated with the risk of mortality and functional decline. Indeed, we found  
377 that patients on multiple antihypertensive medications were at a greater risk for the  
378 composite outcome, even after adjusting for potential confounders. Notably, after  
379 adjusting for the use of loop diuretics, the odds for the risk of the composite outcome  
380 were similar regardless of the number of antihypertensive classes used, suggesting that  
381 loop diuretic usage was a powerful confounding factor associated with mortality and  
382 functional decline. Loop diuretics are indispensable in addressing fluid retention among

383 patients with renal and heart failure. One possible side effect of loop diuretics is  
384 sarcopenia, as discussed in previous studies [10-14]. Na<sup>+</sup>-K<sup>+</sup>-2Cl<sup>-</sup> cotransporter 1,  
385 which is highly expressed in mammalian skeletal muscle and inhibited by furosemide,  
386 might help prevent muscle loss based on its background pharmacological mechanism  
387 [10]; however, the pathological pathway has yet to be not fully elucidated.

388         One strength of the current study is that we used well-validated Japanese  
389 administrative data representing a sample of the general population. The validity of the  
390 diagnoses and procedural records in the Japanese DPC database was corroborated in a  
391 previous study [37]. However, several limitations need to be acknowledged. First, this  
392 study was exclusively conducted on a single race or ethnicity. Evidence suggests that  
393 Asian populations have a higher prevalence of uncontrolled hypertension [38]. Hence,  
394 our findings may not be generalizable to other ethnicities. Second, the use of more than  
395 one antihypertensive drug within the same antihypertensive class was under-represented  
396 in this study. Third, given the nature of the datasets used herein, we were unable to  
397 determine changes in blood pressure and antihypertensive drug use during  
398 hospitalization potentially caused by poor control, complications, or side effects. The  
399 number of antihypertensive classes may have been overestimated. Finally, the database  
400 lacked biochemical data and longitudinal outcomes after discharge. Our study focused

401 only on the effects of antihypertensive medication on postoperative mortality and  
402 functional decline during the acute phase of hospitalization following major surgeries.  
403 A previous multicenter retrospective cohort study showed that the postoperative  
404 initiation of RASis even at discharge was associated with reduced long-term mortality  
405 rate in patients undergoing cardiac surgery [39]. Randomized controlled trials are  
406 needed to determine whether perioperative RASi initiation could improve outcomes  
407 following cardiac and non-cardiac surgeries.

408 In conclusion, the current study highlights the effects of antihypertensive classes  
409 and their combinations on the risk of postoperative mortality and functional decline.  
410 Our findings showed that RASis usage had a positive prognostic impact on  
411 postoperative in-hospital death and functional decline regardless of the number of  
412 antihypertensive medication classes used. Thus, RASi use may mitigate negative  
413 postoperative outcomes after major noncardiac surgeries.

414

#### 415 **Acknowledgments**

416 We would like to thank all study participants.

417

#### 418 **Sources of Funding**

419 This study was supported by the Health and Labour Sciences Research Grant (Grant No.  
420 Seisaku-Sitei-22AA2003 to KF) of the Japan Ministry of Health, Labour and Welfare.

421

422 **Disclosures**

423 **Conflict of interest**

424 None.

425

426 **References**

- 427 1. Zhou B, Carrillo-Larco RM, Danaei G, Riley LM, Paciorek CJ, Stevens GA,  
428 Gregg EW, Bennett JE, Solomon B, Singleton RK, et al. Worldwide trends in  
429 hypertension prevalence and progress in treatment and control from 1990 to 2019: a  
430 pooled analysis of 1201 population-representative studies with 104 million participants.  
431 *Lancet*. 2021;398:957–980.
- 432 2. Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL,  
433 Dennison-Himmelfarb CR, Egan BM, Flack JM, Gidding SS, Judd E, et al. Resistant  
434 hypertension: detection, evaluation, and management: A scientific statement from the  
435 American Heart Association. *Hypertension*. 2018;72:e53–e90.



- 436 3. Persell SD. Prevalence of resistant hypertension in the United States, 2003–2008.  
437 *Hypertension*. 2011;57:1076–1080.
- 438 4. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A,  
439 Cushman WC, White W, Sica D, et al. Resistant hypertension: diagnosis, evaluation,  
440 and treatment. A scientific statement from the American Heart Association Professional  
441 Education Committee of the Council for High Blood pressure research. *Hypertension*.  
442 2008;51:1403–1419.
- 443 5. Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. *Nat*  
444 *Rev Nephrol*. 2020;16:223–237.
- 445 6. Matsuki H, Genma T, Mandai S, Fujiki T, Mori Y, Ando F, Mori T, Susa K,  
446 Iimori S, Naito S, et al. National trends in mortality and urgent dialysis after acute  
447 hypertension in Japan from 2010 through 2019. *Hypertension*. 2023;80:2591–2600.
- 448 7. Dr Onder G, Penninx BWJH, Balkrishnan R, Fried LP, Chaves PH, Williamson  
449 J, Carter C, Di Bari M, Guralnik JM, Pahor M. Relation between use of  
450 angiotensin-converting enzyme inhibitors and muscle strength and physical function in  
451 older women: an observational study. *Lancet*. 2002;359:926–930.
- 452 8. Di Bari M, van de Poll-Franse LV, Onder G, Kritchevsky SB, Newman A,  
453 Harris TB, Williamson JD, Marchionni N, Pahor M, Health, Aging and Body

- 454 Composition Study. Antihypertensive medications and differences in muscle mass in  
455 older persons: the health, aging and body composition study. *J Am Geriatr Soc.*  
456 2004;52:961–966.
- 457 9. Hamroff G, Katz SD, Mancini D, Blaufarb I, Bijou R, Patel R, Jondeau G,  
458 Olivari MT, Thomas S, Le Jemtel TH. Addition of angiotensin II receptor blockade to  
459 maximal angiotensin-converting enzyme inhibition improves exercise capacity in  
460 patients with severe congestive heart failure. *Circulation.* 1999;99:990–992.
- 461 10. Mandai S, Furukawa S, Kodaka M, Hata Y, Mori T, Nomura N, Ando F, Mori Y,  
462 Takahashi D, Yoshizaki Y, et al. Loop diuretics affect skeletal myoblast differentiation  
463 and exercise-induced muscle hypertrophy. *Sci Rep.* 2017;7:46369.
- 464 11. Ishikawa S, Naito S, Iimori S, Takahashi D, Zeniya M, Sato H, Nomura N,  
465 Sohara E, Okado T, Uchida S, et al. Loop diuretics are associated with greater risk of  
466 sarcopenia in patients with nondialysis-dependent chronic kidney disease. *PLOS ONE.*  
467 2018;13:e0192990.
- 468 12. Hanai T, Shiraki M, Miwa T, Watanabe S, Imai K, Suetsugu A, Takai K,  
469 Moriwaki H, Shimizu M. Effect of loop diuretics on skeletal muscle depletion in  
470 patients with liver cirrhosis. *Hepatol Res.* 2019;49:82–95.

- 471 13. Felker GM, O'Connor CM, Braunwald E, Heart Failure Clinical Research  
472 Network Investigators. Loop diuretics in acute decompensated heart failure: necessary?  
473 Evil? A necessary evil? *Circ Heart Fail.* 2009;2:56–62.
- 474 14. Nakano I, Tsuda M, Kinugawa S, Fukushima A, Kakutani N, Takada S, Yokota  
475 T. Loop diuretic use is associated with skeletal muscle wasting in patients with heart  
476 failure. *J Cardiol.* 2020;76:109–114.
- 477 15. Nakano Y, Mandai S, Genma T, Akagi Y, Fujiki T, Ando F, Susa K, Mori T,  
478 Iimori S, Naito S, et al. Nationwide mortality associated with perioperative acute  
479 dialysis requirement in major surgeries. *Int J Surg.* 2022;104:106816.
- 480 16. Isogai T, Yasunaga H, Matsui H, Tanaka H, Horiguchi H, Fushimi K.  
481 Effectiveness of inferior vena cava filters on mortality as an adjuvant to antithrombotic  
482 therapy. *Am J Med.* 2015;128:312.e23–312.e31.
- 483 17. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying  
484 prognostic comorbidity in longitudinal studies: development and validation. *J Chron*  
485 *Dis.* 1987;40:373–383.
- 486 18. Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, Januel JM,  
487 Sundararajan V. Updating and validating the Charlson comorbidity index and score for

- 488 risk adjustment in hospital discharge abstracts using data from 6 countries. *Am J*  
489 *Epidemiol.* 2011;173:676–682.
- 490 19. Bykov K, Bateman BT, Franklin JM, Vine SM, Patorno E. Association of  
491 gabapentinoids with the risk of opioid-related adverse events in surgical patients in the  
492 United States. *JAMA Netw Open.* 2020;3:e2031647.
- 493 20. Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index, *Md Stat.*  
494 *Med J.* 1965;14:61–65.
- 495 21. Kessler M, Frimat L, Panescu V, Briançon S. Impact of nephrology referral on  
496 early and midterm outcomes in ESRD: EPidemiologie de l'insuffisance RENale  
497 chronique terminale en Lorraine (EPIREL): results of a 2-year, prospective,  
498 community-based study. *Am J Kidney Dis.* 2003;42:474–485.
- 499 22. Rethy LB, Feinstein MJ, Achenbach CJ, Townsend RR, Bress AP, Shah SJ,  
500 Cohen JB. Antihypertensive class and cardiovascular outcomes in patients with HIV  
501 and hypertension. *Hypertension.* 2021;77:2023–2033.
- 502 23. Copland E, Canoy D, Nazarzadeh M, Bidel Z, Ramakrishnan R, Woodward M,  
503 Chalmers J, Teo KK, Pepine CJ, Davis BR, et al. Antihypertensive treatment and risk of  
504 cancer: an individual participant data meta-analysis. *Lancet Oncol.* 2021;22:558–570.

- 505 24. Tasheva P, Vollenweider P, Kraege V, Roulet G, Lamy O, Marques-Vidal P,  
506 Méan M. Association between physical activity levels in the hospital setting and  
507 hospital-acquired functional decline in elderly patients. *JAMA Netw Open*.  
508 2020;3:e1920185.
- 509 25. Zhao W, Swanson SA, Ye J, Li X, Shelton JM, Zhang W, Thomas GD. Reactive  
510 oxygen species impair sympathetic vasoregulation in skeletal muscle in angiotensin  
511 II-dependent hypertension. *Hypertension*. 2006;48:637–643.
- 512 26. Brink M, Wellen J, Delafontaine P. Angiotensin II causes weight loss and  
513 decreases circulating insulin-like growth factor I in rats through a pressor-independent  
514 mechanism. *J Clin Invest*. 1996;97:2509–2516.
- 515 27. Dalla Libera L, Ravara B, Angelini A, Rossini K, Sandri M, Thiene G, Battista  
516 Ambrosio G, Vescovo G. Beneficial effects on skeletal muscle of the angiotensin II type  
517 1 receptor blocker irbesartan in experimental heart failure. *Circulation*.  
518 2001;103:2195–2200.
- 519 28. Burks TN, Andres-Mateos E, Marx R, Mejias R, Van Erp C, Simmers JL,  
520 Walston JD, Ward CW, Cohn RD. Losartan restores skeletal muscle remodeling and  
521 protects against disuse atrophy in sarcopenia. *Sci Transl Med*. 2011;3:82ra37.

- 522 29. Hashimoto H, Mandai S, Shikuma S, Kimura M, Toma H, Sakaguchi Y,  
523 Shiraishi S, Toshima N, Hoshino M, Kimura M, et al. The effect of antihypertensive  
524 therapy on skeletal muscle mass and bone mineral density in patients with end-stage  
525 kidney disease. *J Ren Nutr.* 2023. <https://doi.org/10.1053/j.jrn.2023.10.008>.
- 526 30. Steinman MA, Zullo AR, Lee Y, Daiello LA, Boscardin WJ, Dore DD, Gan S,  
527 Fung K, Lee SJ, Komaiko KD, et al. Association of  $\beta$ -blockers with functional  
528 outcomes, death, and rehospitalization in older nursing home residents after acute  
529 myocardial infarction. *JAMA Intern Med.* 2017;177:254–262.
- 530 31. Palau P, Sella J, Domínguez E, Sastre C, Ramón JM, de La Espriella R, Santas  
531 E, Miñana G, Bodí V, Sanchis J, et al. Effect of  $\beta$ -blocker withdrawal on functional  
532 capacity in heart failure and preserved ejection fraction. *J Am Coll Cardiol.*  
533 2021;78:2042–2056.
- 534 32. Mandai S, Koide T, Fujiki T, Mori Y, Ando F, Susa K, Mori T, Iimori S, Naito  
535 S, Sohara E, et al. Association of Admission functional status and body mass index with  
536 mortality in patients receiving chronic dialysis: A nationwide observational cohort study.  
537 *JMA J.* 2023;6:404–413.

- 538 33. Pandey, A, Kitzman, D, Reeves, G. Frailty is intertwined with heart failure:  
539 mechanisms, prevalence, prognosis, assessment, and management. *J Am Coll Cardiol*  
540 HF. 2019;7:1001–1011.
- 541 34. Kulmala J, Nykänen I, Hartikainen S. Frailty as a predictor of all-cause mortality  
542 in older men and women. *Geriatr Gerontol Int*. 2014;14:899–905.
- 543 35. Brummel NE, Bell SP, Girard TD, Pandharipande PP, Jackson JC, Morandi A,  
544 Thompson JL, Chandrasekhar R, Bernard GR, Dittus RS, et al. Frailty and Subsequent  
545 Disability and Mortality among Patients with Critical Illness. *Am J Respir Crit Care*  
546 *Med*. 2017;196:64–72.
- 547 36. Kojima G, Iliffe S, Taniguchi Y, Shimada H, Rakugi H, Walters K. Prevalence  
548 of frailty in Japan: a systematic review and meta-analysis. *J Epidemiol*.  
549 2017;27:347–353.
- 550 37. Yamana H, Moriwaki M, Horiguchi H, Kodan M, Fushimi K, Yasunaga H.  
551 Validity of diagnoses, procedures, and laboratory data in Japanese administrative data. *J*  
552 *Epidemiol*. 2017;27:476–482.
- 553 38. Park JB, Kario K, Wang JG. Systolic hypertension: an increasing clinical  
554 challenge in Asia. *Hypertens Res*. 2015;38:227–236.

555 39. Ding Q, Zhang Z, Liu H, Nie H, Berguson M, Goldhammer JE, Young N, Boyd

556 D, Morris R, Sun J. Perioperative use of renin-angiotensin system inhibitors and

557 outcomes in patients undergoing cardiac surgery. *Nat Commun.* 2019;10:4202.

558

559



560 **Tables**

561 **Table 1. Characteristics of patients aged 50 years and older undergoing major**

562 **surgeries**

	Treatment with antihypertensive medications (n = 473,327)	No treatment (n = 376,583)
Age (year)	76 (69–82)	70 (63–78)
Female	230417 (49)	187556 (50)
BMI (kg/m <sup>2</sup> )	23.4 (20.9–26.0)	22.5 (20.2–24.9)
Barthel Index score		
0–25	82671 (17)	45681 (12)
30–55	23467 (5)	14150 (4)
60–85	24738 (5)	14592 (4)
90–100	342451 (72)	302160 (80)
Cardiovascular disease	82490 (17)	22696 (6)
Diabetes mellitus	123050 (26)	55841 (15)
Chronic kidney disease	25046 (5)	6468 (2)
Emergency admission	134369 (28)	91961 (24)
Major surgeries		
GABG	19617 (4)	167 (0.04)
Lobectomy	37348 (8)	36642 (10)
Orthopedic surgery	212501 (45)	138757 (37)
Surgery for diseases of liver, gall bladder, and pancreas	64788 (14)	63543 (17)
Gastrointestinal resection and esophagectomy	93624 (20)	95305 (25)
Urological surgery	45449 (10)	42169 (11)
Antihypertensive class		
One class	225731 (48)	NA
Two classes	172141 (36)	NA
Three classes	58456 (12)	NA
≥Four classes	16999 (4)	NA
Thiazide and thiazide-like	24625 (5)	NA

---

diuretics		
CCBs	359461 (76)	NA
RASis	258134 (55)	NA
MRA	45190 (10)	NA
Beta blockers	105011 (22)	NA
Alpha blockers	22981 (5)	NA
Loop diuretics	91085 (19)	21782 (6)
Year		
2018	247059 (52)	197997 (53)
2019	226268 (48)	178586 (47)

---

563 Data are presented as number (percentage) or median (interquartile range).

564 BMI, body mass index; CABG, coronary artery bypass grafting; CCB, calcium channel

565 blocker; MRA, mineral corticoid receptor antagonist; RASi,

566 renin–angiotensin–aldosterone system inhibitor; NA, not applicable.

567

568 **Table 2. Number of antihypertensive classes and risk for mortality or functional**  
569 **decline after survival in patients undergoing major surgeries.**

	n/N	Model 1	Model 2	Model 3	Model 4
No antihypertensive drugs	25207/376583	Reference	Reference	Reference	Reference
One class	22063/225731	1.20 (1.18–1.23)	1.20 (1.17–1.22)	1.17 (1.14–1.19)	1.12 (1.10–1.14)
Two classes	17558/172141	1.23 (1.20–1.25)	1.20 (1.18–1.23)	1.14 (1.12–1.17)	1.14 (1.04–1.09)
Three classes	6861/58456	1.42 (1.38–1.47)	1.42 (1.38–1.46)	1.30 (1.26–1.34)	1.11 (1.08–1.15)
≥Four classes	2225/16999	1.57 (1.49–1.65)	1.58 (1.50–1.67)	1.43 (1.36–1.51)	1.12 (1.07–1.19)

570 Model 1: Adjusted for age, sex, and type of major surgeries (CABG, thoracic lobectomy,  
571 orthopedic surgery, hepatopancreatobiliary surgery, gastrointestinal resection, and  
572 urological surgery)

573 Model 2: Model 1 plus BMI and Barthel Index score on admission.

574 Model 3: Model 2 plus DM, CVD, CKD, emergency admission, and admission year.

575 Model 4: Model 3 plus loop diuretics.

576 CABG, coronary artery bypass grafting; BMI, body mass index; DM, diabetes mellitus;

577 CVD, cardiovascular disease; CKD, chronic kidney disease; CI, confidence interval;

578 OR, odds ratio.

579

580 **Table 3. Combinations of antihypertensive classes and perioperative outcomes**

581 **following major surgeries in Japanese adults.**

	Composite outcome		Death		Functional decline	
	OR (95%CI)	P value	OR (95%CI)	P value	OR (95%CI)	P value
<u>One class</u>						
TH	Reference		Reference		Reference	
CCB	0.89 (0.73–1.08)	0.2	0.91 (0.55–1.53)	0.7	0.88 (0.72–1.08)	0.2
RASi	0.77 (0.63–0.93)	0.008	0.58 (0.34–0.99)	0.044	0.79 (0.64–0.97)	0.022
MRA	1.11 (0.91–1.36)	0.3	1.49 (0.88–2.51)	0.1	0.95 (0.76–1.18)	0.6
β-blockers	1.14 (0.92–1.42)	0.2	0.59 (0.31–1.12)	0.1	1.27 (1.01–1.60)	0.040
α-blockers	1.10 (0.90–1.34)	0.4	1.60 (0.95–2.69)	0.1	0.99 (0.80–1.22)	0.9
<u>Two classes</u>						
TH/CCB	Reference		Reference		Reference	
TH/RASi	0.68 (0.60–0.77)	<0.001	0.20 (0.09–0.41)	<0.001	0.76 (0.67–0.86)	<0.001
CCB/RASi	0.78 (0.75–0.82)	<0.001	0.47 (0.41–0.52)	<0.001	0.85 (0.81–0.89)	<0.001
RASi/other	0.80 (0.75–0.86)	<0.001	0.75 (0.65–0.87)	<0.001	0.84 (0.78–0.90)	<0.001
Other/other	1.13 (1.03–1.23)	0.010	1.15 (0.99–1.34)	0.07	1.01 (0.90–1.12)	0.9
<u>Three classes</u>						
TH/CCB/other	Reference		Reference		Reference	
TH/CCB/RASi	0.72 (0.49–0.82)	<0.001	0.43 (0.31–0.60)	<0.001	0.79 (0.70–0.89)	<0.001
TH/RASi/other	0.87 (0.49–1.12)	0.2	0.62 (0.36–1.07)	0.09	0.98 (0.79–1.22)	0.9
CCB/RASi/other	0.82 (0.52–0.86)	<0.001	0.75 (0.63–0.89)	0.001	0.88 (0.80–0.97)	0.011
RASi/others	0.78 (0.50–1.65)	<0.001	0.55 (0.43–0.70)	<0.001	0.91 (0.79–1.05)	0.2
Others	1.66 (1.02–2.69)	0.040	0.72 (0.28–1.81)	0.5	2.19 (1.29–3.72)	0.004
<u>≥Four classes</u>						
TH/CCB/others	Reference		Reference		Reference	
TH/CCB/RASi/ot	0.63 (0.49–0.82)	0.001	0.55 (0.36–0.86)	0.008	0.75 (0.55–1.03)	0.07
TH/RASi/others	0.74 (0.49–1.12)	0.2	0.58 (0.27–1.23)	0.2	0.90 (0.56–1.45)	0.7
CCB/RASi/others	0.67 (0.52–0.86)	0.002	0.50 (0.34–0.76)	0.001	0.83 (0.62–1.13)	0.2
RASi/others	0.91 (0.50–1.65)	0.8	0.55 (0.18–1.65)	0.3	1.25 (0.64–2.46)	0.5

582 Multivariate logistic regression models adjusted for age, sex, type of major surgeries  
583 (CABG, thoracic lobectomy, orthopedic surgery, hepatopancreatobiliary surgery,  
584 gastrointestinal resection, and urological surgery), BMI, Barthel Index score on  
585 admission, DM, CVD, CKD, emergency admission, admission year, and loop diuretics.  
586 CABG, coronary artery bypass grafting; BMI, body mass index; DM, diabetes mellitus;  
587 CVD, cardiovascular disease; CKD, chronic kidney disease; CI, confidence interval;  
588 OR, odds ratio; CCB, calcium channel blocker; MRA, mineral corticoid receptor  
589 antagonist; RASi, renin–angiotensin–aldosterone system inhibitor; TH,  
590 thiazide/thiazide-like diuretics.  
591

592 **Figure legends**

593 **Figure 1. Antihypertensive classes and prevalence of postoperative death or**  
594 **functional decline after survival among patients undergoing major surgeries. a, b.**

595 prevalence of all-cause in-hospital deaths (a) and functional decline (b) among nonusers  
596 and users of one, two, three, or four or more antihypertensive classes according to age  
597 category. Functional decline was defined as a  $\geq 5$ -point decrease in the Barthel Index  
598 score between admission and discharge. Each spot represents a mean, whereas the solid  
599 lines represent the corresponding 95% CI. CI, confidence interval; n/N, number of  
600 events/number of participants.

601 **Figure 2. Association between surgery type and effects of antihypertensive classes**  
602 **on postoperative outcomes among patients with hypertension.** Multivariable logistic

603 regression models adjusted for age, sex, number of antihypertensive classes, BMI,  
604 Barthel Index score on admission, DM, CVD, CKD, emergency admission, year, and  
605 loop diuretics according to surgery type. The type of major surgeries included CABG,  
606 thoracic lobectomy, orthopedic surgery, hepatopancreatobiliary surgery, gastrointestinal  
607 resection, and urological surgery. CABG, coronary artery bypass grafting; BMI, body  
608 mass index; DM, diabetes mellitus; CVD, cardiovascular disease; CKD, chronic kidney  
609 disease; CI, confidence interval; OR, odds ratio; CCB, calcium channel blocker; MRA,


610 mineral corticoid receptor antagonist; RASi, renin–angiotensin–aldosterone system

611 inhibitor.

612

a

## Overall in-hospital death



b

## Survival with functional decline

